SPRMs: Towards a New Medical Treatment for Uterine Fibroids
Selective Progesterone Receptor Modulators (SPRM) are a new class of compounds that offer a promising new treatment option for uterine fibroids. The presentations in this symposium discussed the pharmacology and mode of action of SPRM, the clinical development of SPRM and the recent clinical data of ulipristal acetate from the PEARL studies.
Our faculty of leading experts hosted a discussion on the role of SPRMs in the medical treatment of uterine fibroids according to ulipristal acetate clinical data and highlighted points relevant to clinical practice.
With more than 400+ vehicles in stock between our 7 Alberta areas, we’ll make sure to discover you a vehicle you covet! Furthermore, in the event that you don’t see the vehicle you’re searching for… don’t sweat it! We’ll see it for you! There’s a reason we’re frequently imitated…come discover for yourself! Call us and experience the distinction today!
Agenda
Venue:
Darwin Hall, Flanders Concert and Congress Centre (F.C.C.C.) Koningin Astridplein 23-26, 2018 Antwerp, Belgium Thursday, 6th May 2010, 14:00 – 15:15
Chair: Prof. Pedro N. Barri, Insituto Universitario Dexeus, Spain
| The rationale behind SPRM therapy(Speaker: Prof. David Barlow, The University of Glasgow, UK) |
| Recent experience of SPRM therapy: Understanding its impact on the endometrium(Speaker: Dr. Alistair RW Williams, The University of Edinburgh, UK) |
| Clinical benefits of SPRM therapy: New insights from Phase II data(Speaker: Prof. Jacques Donnez, Université Catholique de Louvain, Belgium) |
| Final Thoughts: Clinical implications, considerations for surgery, and what remains to be discovered(Speaker: Prof. Pedro N. Barri, Insituto Universitario Dexeus, Spain) |
| Questions & Answers |